Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRNNASDAQ:MNPRNASDAQ:NEOSNASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$11.11+1.1%$9.79$7.08▼$18.00$230.08M0.6676,229 shs30,664 shsMNPRMonopar Therapeutics$35.45+0.0%$37.93$1.72▼$54.30$216.78M1.11359,452 shs14,864 shsNEOSNeos Therapeutics$1.15$1.06$0.45▼$1.68$57.22M1.57.44 million shs15.01 million shsRZLTRezolute$3.89-0.3%$3.27$2.22▼$6.19$235.48M1.01589,097 shs431,957 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+0.09%+4.47%+5.07%-6.72%-36.97%MNPRMonopar Therapeutics-0.34%-10.39%-17.50%-11.95%+1,053.27%NEOSNeos Therapeutics0.00%0.00%0.00%0.00%0.00%RZLTRezolute-2.74%+9.55%+25.40%-13.91%+38.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.3678 of 5 stars1.04.00.00.01.50.00.0MNPRMonopar Therapeutics2.8979 of 5 stars3.45.00.00.02.82.50.0NEOSNeos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARZLTRezolute2.6159 of 5 stars3.62.00.00.02.54.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 2.00Hold$7.00-36.99% DownsideMNPRMonopar Therapeutics 2.75Moderate Buy$55.3356.09% UpsideNEOSNeos Therapeutics 0.00N/AN/AN/ARZLTRezolute 3.14Buy$12.14212.16% UpsideCurrent Analyst Ratings BreakdownLatest NEOS, RZLT, MNPR, and AMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.004/28/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.004/2/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/1/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/19/2025MNPRMonopar TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$76.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$214.11M1.07N/AN/A$1.35 per share8.23MNPRMonopar TherapeuticsN/AN/AN/AN/A$1.88 per shareN/ANEOSNeos Therapeutics$64.65M0.89N/AN/A($0.12) per share-9.58RZLTRezoluteN/AN/AN/AN/A$1.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$59.11M-$3.64N/AN/AN/A-16.33%-7.22%-4.96%7/30/2025 (Estimated)MNPRMonopar Therapeutics-$8.40M-$3.48N/AN/AN/AN/A-107.21%-87.57%8/8/2025 (Estimated)NEOSNeos Therapeutics-$16.90M-$0.34N/AN/AN/A-38.35%N/A-28.46%N/ARZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.27%-62.41%N/ALatest NEOS, RZLT, MNPR, and AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MNPRMonopar Therapeutics-$0.65-$0.38+$0.27-$0.38N/AN/A5/13/2025Q3 2025RZLTRezolute-$0.22-$0.27-$0.05-$0.27N/AN/A5/7/2025Q1 2025AMRNAmarin-$0.06-$0.04+$0.02-$0.04$50.75 millionN/A3/31/2025Q4 2024MNPRMonopar Therapeutics-$0.36-$2.23-$1.87-$2.23N/AN/A3/12/2025Q4 2024AMRNAmarin-$1.20-$2.40-$1.20-$0.12$32.37 million$62.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ANEOSNeos TherapeuticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.232.11MNPRMonopar TherapeuticsN/A5.415.41NEOSNeos TherapeuticsN/A0.660.53RZLTRezoluteN/A9.309.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%MNPRMonopar Therapeutics1.83%NEOSNeos Therapeutics33.13%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipAMRNAmarin3.30%MNPRMonopar Therapeutics20.50%NEOSNeos Therapeutics3.80%RZLTRezolute18.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.71 million402.62 millionOptionableMNPRMonopar Therapeutics106.12 million3.97 millionNot OptionableNEOSNeos Therapeutics21349.76 millionN/AOptionableRZLTRezolute4060.54 million49.40 millionOptionableNEOS, RZLT, MNPR, and AMRN HeadlinesRecent News About These CompaniesBrokerages Set Rezolute, Inc. (NASDAQ:RZLT) PT at $12.14May 23 at 2:15 AM | americanbankingnews.comOMERS ADMINISTRATION Corp Invests $372,000 in Rezolute, Inc. (NASDAQ:RZLT)May 22 at 4:23 AM | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of "Buy" from BrokeragesMay 22 at 3:24 AM | marketbeat.comRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateMay 21 at 5:59 AM | finanznachrichten.deHC Wainwright Analysts Lift Earnings Estimates for RezoluteMay 21 at 2:40 AM | marketbeat.comRezolute, Inc. (RZLT): Analysts See 260% Upside PotentialMay 20 at 12:42 PM | finance.yahoo.comCubist Systematic Strategies LLC Sells 92,168 Shares of Rezolute, Inc. (NASDAQ:RZLT)May 20 at 4:09 AM | marketbeat.comFY2025 EPS Estimates for Rezolute Raised by HC WainwrightMay 19, 2025 | americanbankingnews.comRezolute (RZLT) Projected to Post Quarterly Earnings on WednesdayMay 19, 2025 | americanbankingnews.comPoint72 Europe London LLP Purchases New Position in Rezolute, Inc. (NASDAQ:RZLT)May 18, 2025 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Shares Purchased by Dimensional Fund Advisors LPMay 18, 2025 | marketbeat.comWedbush Forecasts Rezolute's FY2025 Earnings (NASDAQ:RZLT)May 18, 2025 | americanbankingnews.comRezolute's (RZLT) Outperform Rating Reiterated at WedbushMay 17, 2025 | americanbankingnews.comRezolute (RZLT) to Release Earnings on WednesdayMay 16, 2025 | marketbeat.comRezolute, Inc. Reports Progress on sunRIZE Enrollment and Breakthrough Therapy Designation for Ersodetug in Hypoglycemia TreatmentMay 16, 2025 | nasdaq.comRezolute, Inc. (NASDAQ:RZLT) Shares Purchased by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLCMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Boosts Stock Holdings in Rezolute, Inc. (NASDAQ:RZLT)May 14, 2025 | marketbeat.comJ. Goldman & Co LP Takes $1.14 Million Position in Rezolute, Inc. (NASDAQ:RZLT)May 14, 2025 | marketbeat.comRezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Sells 272,368 Shares of Rezolute, Inc. (NASDAQ:RZLT)May 13, 2025 | marketbeat.comSusquehanna International Group LLP Buys 788,349 Shares of Rezolute, Inc. (NASDAQ:RZLT)May 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNEOS, RZLT, MNPR, and AMRN Company DescriptionsAmarin NASDAQ:AMRN$11.11 +0.12 (+1.09%) Closing price 04:00 PM EasternExtended Trading$11.18 +0.07 (+0.63%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Monopar Therapeutics NASDAQ:MNPR$35.45 +0.01 (+0.03%) Closing price 04:00 PM EasternExtended Trading$35.45 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Neos Therapeutics NASDAQ:NEOSNeos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.Rezolute NASDAQ:RZLT$3.89 -0.01 (-0.26%) Closing price 04:00 PM EasternExtended Trading$3.87 -0.02 (-0.62%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
